https://fadraciclibinhibitor.c....om/prevalence-along-
Into the 2/3L team, the ORR ended up being 36.4% (95% self-confidence period [CI] 10.9%-69.2%), median DOR was not evaluable, and progression-free survival was 4.70 months. One client (2/3L team) showed limited quality of brain lesions per separate neuroradiologist review. In MET-amplified clients with a MET gene copy wide range of ≥10, the ORR had been 100per cent (2/2 patients) in the 1L team and 45.5% (5/11 clients) in the 2/3L team, with DOR of 8.2 and 8.3 months,
Like
Comment
Share
